◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Unicharm Corporation (8113) Revenue 2022–2025

Name: Unicharm Corporation (8113) revenue history 2022-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-12

Unicharm Corporation annual revenue for fiscal 2025 was JPY 945.3 billion, a decrease of 4.4% from JPY 989.0 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

8113 Annual Revenue

Revenue (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	JPY 945.3B	JPY 989.0B	JPY 941.8B	JPY 898.0B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

8113 Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	JPY 252.9B	JPY 234.2B	JPY 251.0B	JPY 230.1B	JPY 236.7B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

4452 Revenue — Kao Corporation
4911 Revenue — Shiseido Company, Limited
4527 Revenue — Rohto Pharmaceutical Co.,Ltd.
4912 Revenue — Lion Corporation
4967 Revenue — Kobayashi Pharmaceutical Co., Ltd.
8283 Revenue — Paltac Corporation

More 8113 metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All 8113 financial statements → Interactive 8113 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.